Caladrius Biosciences, Inc. (LSTA) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
H.C. Wainwright Reiterates Buy Rating on Lisata Therapeutics, Inc (LSTA)
August 13, 2024 6:04 AM EDTH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $15.00 price target on Lisata Therapeutics, Inc (NASDAQ: LSTA).
The analyst comments "Financial and corporate update. Yesterday after the close, Lisata announced 2Q24 financial results, posting EPS of ($0.61) compared to our estimate of ($0.76)... More



